Can a blood pressure drug reverse liver damage in hepatitis c?

NCT ID NCT00148837

Completed Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver scarring before and after treatment to see if prazosin made a difference.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prazosin
What this could lead to: If it works, adding prazosin to standard therapy could help reduce liver scarring in people with hepatitis C and severe fibrosis.
What could go wrong: This is a small, early-phase trial with only 112 participants. The benefit may be modest or not confirmed in larger studies, and prazosin can cause side effects like dizziness and low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection Fibrosis fibrotic liver disease hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIBROSIS HEPATITIS C, CHRONIC

Contacts and locations

Locations

Hopital du haut Leveque

Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.